MedTech & Diagnostics
Becton Dickinson & Co Executive Compensation (FY25)
BDX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): January 30, 2026
260 figures on this page: 251 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
Thomas Polen, Chairman, Chief Executive Officer and President, received $17,129,140 in total compensation for fiscal 2025, and compared with the $17,314,606 reported for fiscal 2024, Polen's total was 1.1% lower. Separately, for fiscal 2025, the company reported a chief executive pay ratio of 374:1, against median employee compensation of $45,831. Meanwhile, the say-on-pay proposal drew 91.4% of votes cast for or against in favor at the meeting held January 27, 2026 for fiscal 2025. Companies named in the disclosed peer group include Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Boston Scientific Corporation and Danaher Corporation, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Thomas Polen: $17,314,606 → $17,129,140 (1.1% lower)
Say-on-pay support: 89.0% → 91.4% (2.4 points higher)
CEO pay ratio: 396:1 → 374:1 (5.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Becton Dickinson & Co's chief executive and what were they paid?
Thomas Polen, Chairman, Chief Executive Officer and President, received $17,129,140 in total compensation for fiscal 2025. Compared with the $17,314,606 reported for fiscal 2024, Polen's total was 1.1% lower.
What was Becton Dickinson & Co's say-on-pay result?
The say-on-pay proposal drew 91.4% of votes cast for or against in favor at the meeting held January 27, 2026 for fiscal 2025.
Which companies are in Becton Dickinson & Co's peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Boston Scientific Corporation and Danaher Corporation, among others.
What is Becton Dickinson & Co's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 374:1, against median employee compensation of $45,831.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Thomas Polen Chairman, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Christopher DelOrefice Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Thomas Polen Chairman, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Christopher DelOrefice Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Richard Byrd Executive Vice President and President, Interventional Segment | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Thomas Polen Chairman, Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Christopher DelOrefice Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Feld Executive Vice President, Chief Revenue Officer and President, Life Sciences Segment | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Richard Byrd Executive Vice President and President, Interventional Segment | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Christopher J. DelOrefice | RSU | — | — | — | ◇ | — | — | ◇ |
| Christopher J. DelOrefice | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
| Christopher J. DelOrefice | PSU | — | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael C. Feld | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
| Michael C. Feld | RSU | — | — | — | ◇ | — | — | ◇ |
| Michael C. Feld | PSU | — | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael D. Garrison | RSU | — | — | — | ◇ | — | — | ◇ |
| Michael D. Garrison | PSU | — | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael D. Garrison | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
| Richard E. Byrd | PSU | — | ◇ | ◇ | — | ◇ | — | ◇ |
| Richard E. Byrd | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
| Richard E. Byrd | RSU | — | — | — | ◇ | — | — | ◇ |
| Thomas E. Polen | RSU | — | — | — | ◇ | — | — | ◇ |
| Thomas E. Polen | PSU | — | ◇ | ◇ | — | ◇ | — | ◇ |
| Thomas E. Polen | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Richard Byrd | SAR | ◇ | — | ◇ | 11/26/2034 |
| SAR | ◇ | — | ◇ | 11/26/2032 | |
| SAR | ◇ | — | ◇ | 11/26/2031 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | 11/26/2033 | |
| Michael Garrison | RSU | ◇ | ◇ | — | — |
| SAR | ◇ | — | ◇ | 11/26/2032 | |
| SAR | ◇ | — | ◇ | 11/26/2031 | |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | 11/26/2033 | |
| SAR | ◇ | — | ◇ | 11/26/2034 | |
| Christopher DelOrefice | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | 11/26/2034 | |
| SAR | ◇ | — | ◇ | 11/26/2032 | |
| SAR | ◇ | — | ◇ | 11/26/2031 | |
| SAR | ◇ | — | ◇ | 11/26/2033 | |
| Thomas Polen | RSU | ◇ | ◇ | — | — |
| SAR | ◇ | — | ◇ | 11/26/2032 | |
| SAR | ◇ | — | ◇ | 11/26/2034 | |
| SAR | ◇ | — | ◇ | 11/26/2031 | |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | 11/26/2033 | |
| Michael Feld | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | 11/26/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Bertram L. Scott Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
R. Andrew Eckert | ◇ | ◇ | — | — | — | ◇ | ◇ |
Christopher Jones | ◇ | ◇ | — | — | — | ◇ | ◇ |
Catherine M. Burzik | ◇ | ◇ | — | — | — | — | ◇ |
Jeffrey W. Henderson | ◇ | ◇ | — | — | — | — | ◇ |
Carrie L. Byington | ◇ | ◇ | — | — | — | ◇ | ◇ |
Claire M. Fraser | ◇ | ◇ | — | — | — | ◇ | ◇ |
Joanne Waldstreicher | ◇ | ◇ | — | — | — | ◇ | ◇ |
Timothy M. Ring | ◇ | ◇ | — | — | — | — | ◇ |
William M. Brown | ◇ | ◇ | — | — | — | — | ◇ |
Gregory J. Hayes | ◇ | ◇ | — | — | — | — | ◇ |
Thomas E. Polen, Jacqueline Wright and Robert L. Huffines served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual cash retainer ($600,000)
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Agilent Technologies, Inc. A
- Baxter International Inc. BAX
- Boston Scientific Corporation BSX
- Danaher Corporation DHR
- GE Healthcare Technologies, Inc. GEHC
- Medtronic plc MDT
- Stryker Corporation SYK
- Thermo Fisher Scientific Inc. TMO
- Zimmer Biomet Holdings, Inc. ZBH
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | January 27, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | January 28, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | January 23, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | January 24, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | January 25, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | January 26, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | January 28, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | January 22, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | January 23, 2018 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Becton Dickinson & Co disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Becton Dickinson & Co sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
260 figures on this page: 251 cited to the filing that reported them, 9 calculated from figures it prints.
251 cited to the filing
9 calculated from the filing
Documents cited
- 0001628280-26-004393Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-25-057846CEO Pay Ratio · Fiscal 2025 director compensation · Fiscal year 2025 summary compensation table · Grants of Plan-Based Awards · and 3 more sections
- 0000010795-25-000011Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-24-000096Fiscal year 2024 summary compensation table
- 0000010795-24-000006Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-23-000118Fiscal year 2023 summary compensation table
- 0000010795-23-000015Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-22-000007Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-21-000019Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-20-000003Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000010795-19-000004
- 0001628280-18-000557Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Becton Dickinson & Co executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/BDX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Becton Dickinson & Co and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Becton Dickinson & Co discloses
The companies named in BDX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}